C4 Therapeutics Inc is a biotechnology business based in the US. C4 Therapeutics shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. C4 Therapeutics employs 99 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in C4 Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CCCC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
C4 Therapeutics stock price (NASDAQ: CCCC)Use our graph to track the performance of CCCC stocks over time.
C4 Therapeutics shares at a glance
|Latest market close||$43.89|
|52-week range||$23.63 - $51.21|
|50-day moving average||$46.07|
|200-day moving average||$39.62|
|Wall St. target price||$60.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.54|
Buy C4 Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy C4 Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
C4 Therapeutics price performance over time
|1 week (2021-10-11)||4.97%|
|1 month (2021-09-17)||-12.13%|
|3 months (2021-07-19)||11.14%|
|6 months (2021-04-19)||38.98%|
|1 year (2020-10-16)||74.58%|
|2 years (2019-10-15)||N/A|
|3 years (2018-10-15)||N/A|
|5 years (2016-10-15)||N/A|
C4 Therapeutics financials
|Revenue TTM||$33.9 million|
|Gross profit TTM||$-44,273,000|
|Return on assets TTM||-12.93%|
|Return on equity TTM||-32.69%|
|Market capitalisation||$2.1 billion|
TTM: trailing 12 months
Shorting C4 Therapeutics shares
There are currently 2.7 million C4 Therapeutics shares held short by investors – that's known as C4 Therapeutics's "short interest". This figure is 17.5% up from 2.3 million last month.
There are a few different ways that this level of interest in shorting C4 Therapeutics shares can be evaluated.
C4 Therapeutics's "short interest ratio" (SIR)
C4 Therapeutics's "short interest ratio" (SIR) is the quantity of C4 Therapeutics shares currently shorted divided by the average quantity of C4 Therapeutics shares traded daily (recently around 390990.01468429). C4 Therapeutics's SIR currently stands at 6.81. In other words for every 100,000 C4 Therapeutics shares traded daily on the market, roughly 6810 shares are currently held short.
To gain some more context, you can compare C4 Therapeutics's short interest ratio against those of similar companies.
However C4 Therapeutics's short interest can also be evaluated against the total number of C4 Therapeutics shares, or, against the total number of tradable C4 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case C4 Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 C4 Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0626% of the tradable shares (for every 100,000 tradable C4 Therapeutics shares, roughly 63 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against C4 Therapeutics.
Find out more about how you can short C4 Therapeutics stock.
C4 Therapeutics share dividends
We're not expecting C4 Therapeutics to pay a dividend over the next 12 months.
C4 Therapeutics overview
C4 Therapeutics, Inc. , a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.
C4 Therapeutics in the news
C4 Therapeutics initiated with a Market Perform at SVB Leerink
C4 Therapeutics (NASDAQ:CCCC) pulls back 8.2% this week, but still delivers shareholders notable 85% return over 1 year
The Implied Analyst 12-Month Target For FPX
Frequently asked questionsWhat percentage of C4 Therapeutics is owned by insiders or institutions?
Currently 12.868% of C4 Therapeutics shares are held by insiders and 66.657% by institutions. How many people work for C4 Therapeutics?
Latest data suggests 99 work at C4 Therapeutics. When does the fiscal year end for C4 Therapeutics?
C4 Therapeutics's fiscal year ends in December. Where is C4 Therapeutics based?
C4 Therapeutics's address is: 490 Arsenal Way, Watertown, MA, United States, 02472 What is C4 Therapeutics's ISIN number?
C4 Therapeutics's international securities identification number is: US12529R1077
More guides on Finder
How to buy The Real Good Food Company (RGF) stock when it goes public
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
How to buy Lulu’s Fashion Lounge Holdings (LVLU) stock when it goes public
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
How to buy Allarity Therapeutics (ALLR) stock when it goes public
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
How to buy Jupiter Neurosciences (JUNS) stock when it goes public
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
How to buy Mainz Biomed (MYNZ) stock when it goes public
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
How to buy Progressive Care stock when it goes public
Everything we know about the Progressive Care IPO, plus information on how to buy in.
How to buy Desert Peak Minerals (DPM) stock when it goes public
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
How to buy Vaxxinity (VAXX) stock when it goes public
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
How to buy Entrada Therapeutics (TRDA) stock when it goes public
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Today’s trending Reddit stocks
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Ask an Expert